Terms: = Sarcomas AND SMARCA4, hSNF2b, 6597, P51532, BRG1, SNF2L4, SNF2, SWI2, FLJ39786, BAF190, SNF2LB, SNF2-BETA, ENSG00000127616 AND Treatment
42 results:
1. treatment of Thoracic smarca4-Deficient Undifferentiated Tumors: Where We Are and Where We Will Go.
Longo V; Catino A; Montrone M; Montagna ES; Pesola F; Marech I; Pizzutilo P; Nardone A; Perrone A; Gesualdo M; Galetta D
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542211
[TBL] [Abstract] [Full Text] [Related]
2. A rare Ewing-like small round cell tumor in prostate: a case report and literature review.
Wang Z; Ye J; Hu J; Zhang N; Yuan Y
J Cancer Res Clin Oncol; 2024 Mar; 150(3):110. PubMed ID: 38427070
[TBL] [Abstract] [Full Text] [Related]
3. An aggressive case of a thoracic undifferentiated smarca4-deficient tumor with extensive pleural involvement.
Hanona PF; Ezekwudo D; Fullmer J; Allen T; Jaiyesimi I
Thorac Cancer; 2024 Apr; 15(10):847-851. PubMed ID: 38390699
[TBL] [Abstract] [Full Text] [Related]
4. Thoracic smarca4-deficient undifferentiated tumor: A clinicopathological and prognostic analysis of 35 cases and immunotherapy efficacy.
Zhou P; Fu Y; Tang Y; Jiang L; Wang W
Lung Cancer; 2024 Mar; 189():107471. PubMed ID: 38306886
[TBL] [Abstract] [Full Text] [Related]
5. [Cytopathological characteristics of smarca4-deficient thoracic undifferentiated tumors in serous effusion].
Wang WN; Liu XT; Liang YM
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):143-148. PubMed ID: 38281781
[No Abstract] [Full Text] [Related]
6. A CIC-related-epigenetic factors-based model associated with prediction, the tumor microenvironment and drug sensitivity in osteosarcoma.
Yu B; Geng C; Wu Z; Zhang Z; Zhang A; Yang Z; Huang J; Xiong Y; Yang H; Chen Z
Sci Rep; 2024 Jan; 14(1):1308. PubMed ID: 38225273
[TBL] [Abstract] [Full Text] [Related]
7. Characterization of a Preclinical In Vitro Model Derived from a smarca4-Mutated Sinonasal Teratocarcinosarcoma.
Lorenzo-Guerra SL; Codina-Martínez H; Suárez-Fernández L; Cabal VN; García-Marín R; Riobello C; Vivanco B; Blanco-Lorenzo V; Sánchez-Fernández P; López F; Llorente JL; Hermsen MA
Cells; 2023 Dec; 13(1):. PubMed ID: 38201285
[TBL] [Abstract] [Full Text] [Related]
8. Thoracic smarca4-deficient undifferentiated tumor: current knowledge and future perspectives.
Shinno Y; Ohe Y;
Jpn J Clin Oncol; 2024 Mar; 54(3):265-270. PubMed ID: 38117955
[TBL] [Abstract] [Full Text] [Related]
9. PROTAC-Based Protein Degradation as a Promising Strategy for Targeted Therapy in sarcomas.
Mancarella C; Morrione A; Scotlandi K
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003535
[TBL] [Abstract] [Full Text] [Related]
10. Expanding a precision medicine platform for malignant peripheral nerve sheath tumors: New patient-derived orthotopic xenografts, cell lines and tumor entities.
Creus-Bachiller E; Fernández-Rodríguez J; Magallón-Lorenz M; Ortega-Bertran S; Navas-Rutete S; Romagosa C; Silva TM; Pané M; Estival A; Perez Sidelnikova D; Morell M; Mazuelas H; Carrió M; Lausová T; Reuss D; Gel B; Villanueva A; Serra E; Lázaro C
Mol Oncol; 2024 Apr; 18(4):895-917. PubMed ID: 37798904
[TBL] [Abstract] [Full Text] [Related]
11. Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial.
Blay JY; Chevret S; Le Cesne A; Brahmi M; Penel N; Cousin S; Bertucci F; Bompas E; Ryckewaert T; Soibinet P; Boudou-Rouquette P; Saada Bouzid E; Soulie P; Valentin T; Lotz JP; Tosi D; Neviere Z; Cancel M; Ray-Coquard I; Gambotti L; Legrand F; Lamrani-Ghaouti A; Simon C; Even C; Massard C
Lancet Oncol; 2023 Aug; 24(8):892-902. PubMed ID: 37429302
[TBL] [Abstract] [Full Text] [Related]
12. Tazemetostat for tumors harboring SMARCB1/smarca4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C.
Chi SN; Yi JS; Williams PM; Roy-Chowdhuri S; Patton DR; Coffey BD; Reid JM; Piao J; Saguilig L; Alonzo TA; Berg SL; Ramirez NC; Jaju A; Mhlanga JC; Fox E; Hawkins DS; Mooney MM; Takebe N; Tricoli JV; Janeway KA; Seibel NL; Parsons DW
J Natl Cancer Inst; 2023 Nov; 115(11):1355-1363. PubMed ID: 37228094
[TBL] [Abstract] [Full Text] [Related]
13. Pathological characteristics and immune microenvironment of smarca4-deficient undifferentiated uterine sarcoma.
Gao J; Fan R; Chen D; Hou J; Chen H; Lu M
Diagn Pathol; 2023 May; 18(1):62. PubMed ID: 37194064
[TBL] [Abstract] [Full Text] [Related]
14. Promising efficacy of immune checkpoint inhibitor plus chemotherapy for thoracic smarca4-deficient undifferentiated tumor.
Lin Y; Yu B; Sun H; Zhang H; Hu Z; Zhang Y; Wu Z; Sun S; Zhao X; Yu H; Wu X; Li Y; Wang J; Wang H
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8663-8671. PubMed ID: 37115272
[TBL] [Abstract] [Full Text] [Related]
15. [Thoracic
Xiong Y; Zhang B; Nie LG; Wu SK; Zhao H; Li D; DI JT
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):351-356. PubMed ID: 37042149
[TBL] [Abstract] [Full Text] [Related]
16. Identification and treatment of smarca4 Deficient Poorly Differentiated Gastric Carcinoma.
Bhat V; Koneru M; Knapp K; Joneja U; Morrison J; Hong YK
Am Surg; 2023 Nov; 89(11):4987-4989. PubMed ID: 36533880
[TBL] [Abstract] [Full Text] [Related]
17. smarca4-deficient undifferentiated tumor that responded to chemotherapy in combination with immune checkpoint inhibitors: A case report.
Utsumi T; Taniguchi Y; Noda Y; Fukai M; Kibata K; Murakawa T
Thorac Cancer; 2022 Aug; 13(15):2264-2266. PubMed ID: 35778998
[TBL] [Abstract] [Full Text] [Related]
18. Immune-Desert Tumor Microenvironment in Thoracic smarca4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors.
Gantzer J; Davidson G; Vokshi B; Weingertner N; Bougoüin A; Moreira M; Lindner V; Lacroix G; Mascaux C; Chenard MP; Bertucci F; Davidson I; Kurtz JE; Sautès-Fridman C; Fridman WH; Malouf GG
Oncologist; 2022 Jun; 27(6):501-511. PubMed ID: 35278076
[TBL] [Abstract] [Full Text] [Related]
19. Thorahcic smarca4-deficient undifferentiated tumors with ganglioneuroma and enchondroma: implications for SLC7A11 and ARID1A expression: a case report.
Kito Y; Kawashima K; Saigo C; Hasegawa M; Nomura S; Mikamo T; Hanamatsu Y; Matsuo Y; Takeuchi T
Diagn Pathol; 2022 Feb; 17(1):29. PubMed ID: 35151345
[TBL] [Abstract] [Full Text] [Related]
20. Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with smarca4-deficient thoracic sarcoma.
Kawachi H; Kunimasa K; Kukita Y; Nakamura H; Honma K; Kawamura T; Inoue T; Tamiya M; Kuhara H; Nishino K; Mizote Y; Akazawa T; Tahara H; Kumagai T
Immunotherapy; 2021 Jul; 13(10):799-806. PubMed ID: 34030451
[TBL] [Abstract] [Full Text] [Related]
[Next]
